FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
Go back to FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease| (NASDAQ: IBRX) | Delayed: 8.64 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.64 | 52 Week High | $ | |||
| Open | $8.64 | 52 Week Low | $ | |||
| Day High | $8.64 | P/E | N/A | |||
| Day Low | $8.64 | EPS | $ | |||
| Volume | 3,064 | |||||



